T Cell News and Research

Latest T Cell News and Research

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

Medtronic, Inc. today announced study results from an oral presentation at the International Diabetes Federation’s World Diabetes Congress held in Montreal, Canada. This scientific convention highlights the latest developments in clinical research aimed at improving diabetes management and outcomes.

23 Oct 2009

CellAura to provide pharmacologically validated reagents for Cisbio Bioassays' cellular studies

CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays’ Tag-lite™ range of non-radioactive assays for cellular studies.

23 Oct 2009

New method devised for harvesting purified protein molecules

Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.

23 Oct 2009

Affymax to make multiple presentations on preclinical and clinical data of Hematide

Affymax, Inc. today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.

23 Oct 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.

22 Oct 2009

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

Progenika to provide blood group genotyping reference laboratory services to ARUP

Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Scientists explore new molecular insights for treating anxiety disorders

There are increasingly precise molecular insights into ways that stress exposure leads to fear and through which fear extinction resolves these fear states. Extinction is generally regarded as new inhibitory learning, but where the inhibition originates from remains to be determined.

22 Oct 2009

Industries oppose proposed assisted living regulations

With Pennsylvania just weeks away from the publication of final assisted living regulations, recently-released survey results about the size of living units in existing facilities show the wisdom of the proposed rules -- and the absurdity of the industry's opposition.

22 Oct 2009

HBO treatments may improve neurological outcome after traumatic brain injury

Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored.

22 Oct 2009

Researchers develop a non-invasive test to help assess embryo viability for IVF

Embryos that are most likely to result in a pregnancy are crucial to the success of in vitro fertilization (IVF) but are difficult to identify. Researchers at Yale School of Medicine, led by Emre Seli, M.D., are developing a fast, non-invasive test to help assess embryo viability for IVF.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

T Cell News and Research

Latest T Cell News and Research

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

CellAura to provide pharmacologically validated reagents for Cisbio Bioassays' cellular studies

New method devised for harvesting purified protein molecules

Affymax to make multiple presentations on preclinical and clinical data of Hematide

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Rosetta Genomics, GTG sign exclusive distribution agreement

Progenika to provide blood group genotyping reference laboratory services to ARUP

Celgene announces fiscal 2009 third-quarter results

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Scientists explore new molecular insights for treating anxiety disorders

Industries oppose proposed assisted living regulations

HBO treatments may improve neurological outcome after traumatic brain injury

Researchers develop a non-invasive test to help assess embryo viability for IVF

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in